About the Company
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
Employees
10
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CTXR News
Citius Pharmaceuticals Inc CTXR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program
CRANFORD, N.J., March 7, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company ...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
NOTE: This content is not written by or endorsed by "KOIN", its advertisers, or Nexstar Media Inc.
Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Facts
Citius Pharmaceuticals, Inc. (CTXR) announced the FDA has accepted the resubmission of the Biologics License Application for LYMPHIR, ...
Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct ...
Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Facts
(RTTNews) - Citius Pharmaceuticals, Inc. (CTXR) announced the FDA has accepted the resubmission of the Biologics License Application for LYMPHIR, an IL-2-based immunotherapy for the treatment of ...
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
Likewise, our upcoming end of Phase 2 meeting with the FDA should provide valuable input on the development plan for Halo-Lido," stated Leonard Mazur, Chairman and CEO of Citius. "Importantly, we ...
Citius Pharmaceuticals Inc CTXR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Citius Pharmaceuticals Inc (CTXR)
Investing.com - Citius Pharma (NASDAQ: CTXR) reported third quarter EPS of $-0.060, in line with the analyst estimate of $-0.060. Revenue for the quarter came in at $0.00 versus... Citius Pharma ...
Loading the latest forecasts...